SCHEMBL1027720

SCHEMBL1027720

FC(F)Oc1ccc(CCl)cc1OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 4/20 0.43
PDE4A P27815 3/20 0.43
PDE4C Q08493 3/20 0.43
PDE4D Q08499 3/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ATM Q13315 1/20 0.42
TTR P02766 1/20 0.42
SLC2A1 P11166 1/20 0.42
PTGER1 P34995 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6739512 0.94 PDE4B (0.43) PDE4BPDE4APDE4CPDE4DKMT2A
SCHEMBL2074825 0.86 SLC2A1 (0.52) KMT2AMEN1ATMTTRSLC2A1
SCHEMBL20064613 0.85 MAPK1 (0.46) PDE4BPDE4APDE4CPDE4DKMT2A
SCHEMBL1033829 0.85 PDE4A (0.46) PDE4BPDE4APDE4CPDE4DTTR
SCHEMBL20064612 0.84 SLC6A4 (0.56) KMT2AMEN1ATMPTGER1SMN1; SMN2
SCHEMBL7418774 0.82 PDE4A (0.42) PDE4BPDE4APDE4CPDE4DKMT2A
SCHEMBL20063944 0.82 FFAR1 (0.46) PDE4BPDE4APDE4CPDE4DPTGER1
SCHEMBL1030549 0.82 PDE4A (0.40) PDE4BPDE4APDE4CPDE4DKMT2A
SCHEMBL10934702 0.81 MAPT (0.53) PDE4BPDE4APDE4CPDE4DSMN1; SMN2
SCHEMBL23981779 0.81 MAPT (0.47) PDE4BPDE4APDE4CPDE4DPTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1481969-B1 PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2011-01-19 EP disclosed
EP-1481969-B1 PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2011-01-19 EP disclosed
US-7425567-B2 Piperidine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-09-16 US disclosed
US-7425567-B2 Piperidine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-09-16 US disclosed
US-7425567-B2 Piperidine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-09-16 US disclosed
US-20050080107-A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-04-14 US disclosed
EP-1481969-A1 PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080107-A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient PDCD4, PDE4B, IRAK4 PDE4B 2/4885PDE4A 7/4885PDE4C 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.